4677-18-3

Usage

Uses

Used in Organic Synthesis:
2-(Tetrahydro-pyran-4-yl)-ethanol serves as a key building block in the preparation of a variety of pharmaceuticals, agrochemicals, and fine chemicals. Its unique tetrahydropyran ring structure contributes to the formation of complex molecular architectures, enhancing the compound's utility in the synthesis of diverse chemical entities.
Used as a Solvent and Reagent in Chemical Reactions:
Due to its solubility and stability, 2-(Tetrahydro-pyran-4-yl)-ethanol is employed as a solvent and reagent in various chemical reactions. Its ability to dissolve a wide range of substances and participate in reactions without compromising the integrity of the reactants makes it a preferred choice in many chemical processes.
Used in the Flavor and Fragrance Industry:
2-(Tetrahydro-pyran-4-yl)-ethanol has potential applications in the flavor and fragrance industry, where its unique properties can contribute to the creation of novel scents and tastes. Its compatibility with a variety of organic compounds allows for the development of innovative and complex fragrances and flavor profiles.
Used in Medicinal Applications:
2-(Tetrahydro-pyran-4-yl)-ethanol has been studied for its potential medicinal properties, including antimicrobial and antiparasitic activities. Its ability to interact with biological systems at the molecular level positions it as a candidate for the development of new therapeutic agents targeting a range of diseases and conditions.

InChI:InChI=1/C7H14O2/c8-4-1-7-2-5-9-6-3-7/h7-8H,1-6H2

Upstream product

• 103260-44-2 ethyl tetrahydropyran-4-acetate 
• 130312-00-4 ethyl tetrahydro-4H-pyran-4-ylideneacetate 
• 85064-61-5 2-(tetrahydro-2H-pyran-4-yl)acetic acid 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 57056-39-0 3-carboxymethylglutaric acid 

Downstream Products

• 65626-23-5 2-(tetrahydro-2H-pyran-4-yl)acetaldehyde 
• 959748-73-3 2-(tetrahydro-2H-pyran-4-yl)ethyl 4-methylbenzenesulfonate 
• 946619-93-8 C₄₀H₄₄F₄N₄O₆S 
• 100-76-5 Quinuclidine 
• 1312019-24-1 1-(1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-2-(tetrahydro-pyran-4-yl)-ethanol 
• 1312016-61-7 5-methoxy-2-[2-(tetrahydro-pyran-4-yl)-1-(4-trifluoromethyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1312019-28-5 2-[1(R)-(4-methanesulfonyl-phenyl)-2-(tetrahydro-pyran-4-yl)-ethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1312017-00-7 2-[2-(tetrahydro-pyran-4-yl)-1-(4-trifluoromethyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1312018-43-1 1-(1-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2-(tetrahydro-pyran-4-yl)-ethanol 
• 1312018-45-3 toluene-4-sulfonic acid-1-(1-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)-2-(tetrahydro-pyran-4-yl)-vinyl ester 
• 1312018-46-4 1-benzenesulfonyl-2-[1-(4-methanesulfonyl-phenyl)-2-(tetrahydro-pyran-4-yl)-vinyl]-5-methoxy-1H-pyrrolo[2,3-b]pyridine 
• 1312018-47-5 2-[1-(4-methanesulfonyl-phenyl)-2-(tetrahydro-pyran-4-yl)-vinyl]-5-methoxy-1H-pyrrolo[2,3-b]pyridine 
• 1312016-57-1 2-[1-(4-methanesulfonyl-phenyl)-2-(tetrahydro-pyran-4-yl)-ethyl]-5-methoxy-1H-pyrrolo[2,3-b]pyridine 
• 1312018-48-6 1-benzenesulfonyl-5-methoxy-2-[2-(tetrahydro-pyran-4-yl)-1-(4-trifluoromethyl-phenyl)-vinyl]-1H-pyrrolo[2,3-b]pyridine 

Relevant academic research and scientific papers

Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors

ATAD2 is a cancer-associated protein whose bromodomain has been described as among the least druggable of its class. In our recent disclosure of the first chemical probe against this bromodomain, GSK8814 (6), we described the use of a conformationally constrained methoxy piperidine to gain selectivity over the BET bromodomains. Here we describe an orthogonal conformational restriction strategy of the piperidine ring to give potent and selective tropane inhibitors and show structural insights into why this was more challenging than expected. Greater understanding of why different rational approaches succeeded or failed should help in the future design of selectivity in the bromodomain family.

DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions co

ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (S-I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

Dihydropyrrolopyridine inhibitors of ROR-gamma

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions co

EP1 RECEPTOR LIGANDS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

Compounds Which Selectively Modulate The CB2 Receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

TETRAZOLE COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally usefu

AZAINDOLE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

PURINE DERIVATIVES AS IMMUNOMODULATORS

The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants

Synthesis of bicyclic tertiary α-amino acids

Novel bicyclic α-amino acids, exo and endo-1-azabicyclo-[2.2.1] heptane-2-carboxylic acid, 1-azabicyclo[2.2.1]heptane-7-carboxylic acid, and 1-azabicyclo[3.2.2]nonane-2-carboxylic acid have been readily synthesized for the generation of neuronal nicotinic receptor ligands. Alkylation of glycine-derived Schiff bases or nitroacetates with cyclic ether electrophiles, followed by acid-induced ring opening and cyclization in NH4OH, allowed for the preparation of substantial quantities of the three tertiary bicyclic α-amino acids.